H. Faber

发表

Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans

J. Urquhart, M. Danhof, D. Breimer, 1987, Clinical pharmacology and therapeutics.

Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.

M. Danhof, N. Vermeulen, D. Breimer, 1984, Biochemical pharmacology.

Transdermal fentanyl for the treatment of back pain caused by vertebral osteoporosis

D. Felsenberg, H. Minne, M. Pfeifer, 2002, Rheumatology International.

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study.

H. Faber, J. Ringe, A. Dorst, 2001, The Journal of clinical endocrinology and metabolism.

Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.

J. Ringe, H. Faber, E. Schacht, 2005, The Journal of rheumatology. Supplement.

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study

P. Farahmand, J. Ringe, H. Faber, 2008, Rheumatology International.

Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis

J. Ringe, V. Rahlfs, H. Faber, 2004, Rheumatology International.

Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate

H. Faber, J. Ringe, A. Dorst, 2005, Osteoporosis International.

Influence of Haemodialysis on the Pharmacokinetics and Haemodynamic Effects of Nifedipine During Continuous Intravenous Infusion

D. Breimer, A. Woittiez, C. Kleinbloesem, 1986, Clinical pharmacokinetics.

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

P. Farahmand, J. Ringe, H. Faber, 2006, Rheumatology International.

Rapid pain relief and remission of sternocostoclavicular hyperostosis after intravenous ibandronate therapy

P. Farahmand, J. Ringe, H. Faber, 2005, Journal of Bone and Mineral Metabolism.

Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.

J. Ringe, H. Faber, A. Dorst, 2003, Rheumatology.

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

J. Ringe, H. Faber, A. Dorst, 2003, Osteoporosis International.

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

J. Ringe, H. Faber, A. Dorst, 2004, Rheumatology International.

Pharmacokinetics and Hemodynamic Effects of Long‐Term Nifedipine Treatment in Hypertensive Patients

D. Breimer, P. van Brummelen, C. Kleinbloesem, 1987, Journal of cardiovascular pharmacology.

Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study

L. Rovati, H. Faber, I. Setnikar, 2005, Rheumatology International.